Margriet Kwint

Chapter 3 62 Variable HR (OS) univariate P-value (OS) univariate HR (OS) multivariate P-value (OS) multivariate HR (PFS) univariate P-value (PFS) univariate HR (PFS) multivariate P-value (PFS) multivariate Location metastasis Brain 1.000 1.000 Other than brain 0.858 0.648 0.944 0.827 Systemic treatment 2 yes 1.000 1.000 no 0.973 0.955 0.963 0.916 Systemic treatment Sequential 1.000 1.000 Concurrent 0.847 0.785 1.791 0.131 No systemic treatment 0.957 0.927 1.031 0.934 Discussion This observational study showed the results of 91 consecutive NSCLC patients diagnosed with oligometastatic disease who were selected for a radical treatment of the primary tumor and the metastasis. Stage IV NSCLC patients are considered incurable and are mainly treated with palliative intent. With the introduction of oligometastatic NSCLC disease as a separate entity, a more radical treatment approach is increasingly applied in current medical practice. However, the literature on outcome of patients with synchronous oligometastatic NSCLC treated radically is scarce. To our best knowledge this is one of the largest studies analyzing the outcome of a radical treatment with synchronous oligometastatic NSCLC patients. The OS of 32 months and 1- and 2-year OS rates of 85% and 58% and a PFS of 14 months illustrate the favorable outcome in this patient group [3]. Compared to stage IV NSCLC patients who were treated with palliative chemotherapy (1-year OS of 29%) [3], OS is considerably better, which is at least in part due to the favorable prognostic profile of patients with oligometastatic disease [28].Uyterlinde et.al . [29] published the treatment outcome of locally advanced NSCLC patients treated with concurrent chemoradiation in our institute; the 2-year OS was 52% and PFS was 18.1 months. Although results may be confounded by selection bias, our current results show that the outcome of radical treatment of a selected population oligometastatic NSCLC patients is comparable with the treatment of locally advanced